BioRegenx Balance Sheet Health
Financial Health criteria checks 2/6
BioRegenx has a total shareholder equity of $17.0M and total debt of $2.0M, which brings its debt-to-equity ratio to 11.7%. Its total assets and total liabilities are $20.5M and $3.5M respectively.
Key information
11.7%
Debt to equity ratio
US$1.99m
Debt
Interest coverage ratio | n/a |
Cash | US$189.27k |
Equity | US$17.01m |
Total liabilities | US$3.50m |
Total assets | US$20.52m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BRGX's short term assets ($928.1K) do not cover its short term liabilities ($3.4M).
Long Term Liabilities: BRGX's short term assets ($928.1K) exceed its long term liabilities ($150.0K).
Debt to Equity History and Analysis
Debt Level: BRGX's net debt to equity ratio (10.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if BRGX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BRGX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BRGX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 49.4% each year